Alessandro Dal Maso
Padova, 35100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease.
Journal: The oncologist
Published: April 10, 2025
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancer.
Journal: Frontiers in oncology
Published: December 28, 2024
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 09, 2024
Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis.
Journal: Frontiers in oncology
Published: April 10, 2024
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.
Journal: Frontiers in immunology
Published: December 11, 2023
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Journal: The oncologist
Published: October 17, 2023
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.
Journal: Frontiers in immunology
Published: October 05, 2023
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Journal: Clinical lung cancer
Published: August 22, 2023
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
Journal: The oncologist
Published: April 05, 2023
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments.
Journal: Cancers
Published: October 04, 2022
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience.
Journal: Journal of thoracic disease
Published: June 02, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 13, 2022
Last Updated: 09/26/2026